» Articles » PMID: 32239371

Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives

Overview
Publisher Springer
Date 2020 Apr 3
PMID 32239371
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: CXCR4 is one of several "chemokine" receptors expressed on malignant tumors (including GBM and PCNSL) and hematopoietic stem cells. Although Ga-pentixafor and Ga-NOTA-NFB have been shown to effectively image CXCR4 expression in myeloma and other systemic malignancies, imaging CXCR4 expression in brain tumors has been more limited due to the blood-brain barrier (BBB) and a considerable fraction of CXCR4 staining is intracellular.

Methods: We synthesized 6 iodinated and brominated cyclam derivatives with high affinity (low nM range) for CXCR4, since structure-based estimates of lipophilicity suggested rapid transfer across the BBB and tumor cell membranes.

Results: We tested 3 iodinated and 3 brominated cyclam derivatives in several CXCR4(+) and CXCR4(-) cell lines, with and without cold ligand blocking. To validate these novel radiolabeled cyclam derivatives for diagnostic CXCR4 imaging efficacy in brain tumors, we established appropriated murine models of intracranial GBM and PCNSL. Based on initial studies, I-HZ262 and Br-HZ270-1 were shown to be the most avidly accumulated radioligands. Br-HZ270-1 was selected for further study in the U87-CXCR4 and PCNSL #15 intracranial tumor models, because of its high uptake (9.5 ± 1.3 %ID/g, SD) and low non-specific uptake (1.6 ± 0.7 %ID/g, SD) in the s.c. U87-CXCR4 tumor models. However, imaging CXCR4 expression in intracranial U87-CXCR4 and PCNSL #15 tumors with Br-HZ270-1 was unsuccessful, following either i.v. or spinal-CSF injection.

Conclusions: Imaging CXCR4 expression with halogenated cyclam derivatives was successful in s.c. located tumors, but not in CNS located tumors. This was largely due to the following: (i) the hydrophilicity of the radiolabeled analogues-as reflected in the "measured" radiotracer distribution (LogD) in octanol/PBS-which stands in contrast to the structure-based estimate of LogP, which was the rationale for initiating the study and (ii) the presence of a modest BTB in intracranial U87-CXCR4 gliomas and an intact BBB/BTB in the intracranial PCNSL animal model.

Citing Articles

CXCL12 impact on glioblastoma cells behaviors under dynamic culture conditions: Insights for developing new therapeutic approaches.

El Kheir W, Naasri S, Marcos B, Virgilio N, Paquette B, Faucheux N PLoS One. 2024; 19(12):e0315038.

PMID: 39715221 PMC: 11665989. DOI: 10.1371/journal.pone.0315038.


Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.

Wang Y, Gao F Korean J Radiol. 2023; 24(9):871-889.

PMID: 37634642 PMC: 10462898. DOI: 10.3348/kjr.2023.0091.


CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.

Yu J, Zhou X, Shen L Molecules. 2023; 28(12).

PMID: 37375261 PMC: 10304366. DOI: 10.3390/molecules28124707.


Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.

Zhai Y, Zhou X, Wang X Ther Adv Med Oncol. 2022; 14:17588359221093745.

PMID: 35558005 PMC: 9087239. DOI: 10.1177/17588359221093745.


In Vivo Targeting of CXCR4-New Horizons.

Schottelius M, Herrmann K, Lapa C Cancers (Basel). 2021; 13(23).

PMID: 34885030 PMC: 8656854. DOI: 10.3390/cancers13235920.

References
1.
Stevenson C, Ehtesham M, McMillan K, Valadez J, Edgeworth M, Price R . CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. Neurosurgery. 2008; 63(3):560-9. PMC: 2602832. DOI: 10.1227/01.NEU.0000324896.26088.EF. View

2.
Smith J, Falkenhagen K, Coupland S, Chipps T, Rosenbaum J, Braziel R . Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol. 2007; 127(4):633-41. DOI: 10.1309/NUQHJ79BHWYD9TAF. View

3.
Wang Z, Zhang M, Wang L, Wang S, Kang F, Li G . Prospective Study of (68)Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients. Theranostics. 2015; 5(8):882-9. PMC: 4440444. DOI: 10.7150/thno.12303. View

4.
Aghanejad A, Jalilian A, Fazaeli Y, Alirezapoor B, Pouladi M, Beiki D . Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4. Sci Pharm. 2014; 82(1):29-42. PMC: 3951231. DOI: 10.3797/scipharm.1305-18. View

5.
De Clercq E . The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol. 2009; 77(11):1655-64. DOI: 10.1016/j.bcp.2008.12.014. View